Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? (Q44289368)

1 December 2017

Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? (English)

1 reference

polycystic ovary syndrome

1 December 2017

0 references

1 reference

1 reference

1 reference

1 reference

11

1 reference

1 December 2017

4

Libuse Tauchmanovà

1 reference

1 December 2017

13

Gaetano Lombardi

1 reference

1 December 2017

12

Annamaria Colao

1 reference

1 December 2017

2

Stefano Palomba

1 reference

1 December 2017

9

Silvia Savastano

1 reference

1 December 2017

Francesco Orio

1

1 reference

1 December 2017

Teresa Cascella

3

1 reference

1 December 2017

Luciano G Nardo

5

1 reference

1 December 2017

Sebastiano Di Biase

6

1 reference

1 December 2017

Donato Labella

7

1 reference

1 December 2017

Tiziana Russo

8

1 reference

1 December 2017

Achille Tolino

10

1 reference

1 December 2017

language of work or name

1 reference

1 November 2004

1 reference

Reproductive BioMedicine Online

1 December 2017

1 reference

1 December 2017

9

1 reference

1 December 2017

505-510

1 reference

1 December 2017

5

1 reference

Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Increased plasma plasminogen activator inhibitor-1 levels: a possible marker of hypertensive target organ damage

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Plasminogen-activator inhibitor type 1 and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Polycystic ovary syndrome: the new millenium

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

The adipocyte and hemostatic balance in obesity: studies of PAI-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Fibrinolytic activity and clotting factors in ischaemic heart disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Evaluation of assays available to measure free testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Growth hormone secretion after baclofen administration in different phases of the menstrual cycle in healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Circulating ghrelin concentrations in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: a novel principle

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

The pathophysiology of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961634-3

7 January 2021

10.1016/S1472-6483(10)61634-3

Identifiers

DOI

1 reference

1 December 2017

1 reference